Pd 1 Resistant Head And Neck Cancer Market Insight

DelveInsight’s ‘PD-1 Resistant Head and Neck Cancer—Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.


The PD-1 Resistant Head and Neck Cancer market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted PD-1 Resistant Head and Neck Cancer symptoms market size from 2018 2030 segmented by the major markets. The report also covers current PD-1 Resistant Head and Neck Cancer symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China
  • South Korea
  • Taiwan

Study Period: 2018–2030

PD-1 Resistant Head and Neck Cancer Disease Understanding and Treatment Algorithm

PD-1 Resistant Head and Neck Cancer Overview

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease encompassing various tumors that originate in the hypopharynx, oropharynx, lip, oral cavity, nasopharynx, or larynx. The disease group as a whole is associated with different epidemiology, etiology, and therapy. Worldwide, it represents the sixth most common neoplasia and accounts for 6% of all cases, being responsible approximately for 1–2% of tumor deaths.


The three main types of treatment for managing head and neck cancer were radiation therapy, surgery, and chemotherapy. However, the survival rate for head and neck cancer is quite low due to its ability to evade the immune response. Immune escape and T cell exhaustion are mechanisms used by Head and Neck cancer for cancer survival in the tumor microenvironment. Several immune checkpoint inhibitors have been approved for cancer which has significantly improved the survival rate.


PD-1 Resistant Head and Neck Cancer Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the PD-1 Resistant Head and Neck Cancer market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, Japan, China, South Korea, and Taiwan.


The DelveInsight PD-1 Resistant Head and Neck Cancer market report give a thorough understanding of PD-1 Resistant Head and Neck Cancer symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides PD-1 Resistant Head and Neck Cancer symptoms of treatment algorithms and treatment guidelines for PD-1 Resistant Head and Neck Cancer symptoms in the US, Europe, Japan, China, South Korea, and Taiwan.


If a person has symptoms and signs of head and neck cancer, the doctor will take a complete medical history, noting all symptoms and risk factors. During a physical examination, the doctor feels for any lumps on the neck, lips, gums, and cheeks. The doctor will also inspect the nose, mouth, throat, and tongue for abnormalities, often using a light and a mirror for a clearer view. Blood and urine tests may be done to help diagnose cancer. Also, the biopsy may include testing to see whether the person has HPV. As described in Risk Factors and Prevention, HPV has been linked to a higher risk of some head and neck cancers. In some cases, whether a person has HPV can also be a factor in determining which treatments are likely to be most effective.


Due to the inconclusive evidence for available treatment options, the management of RD varies among practitioners. Most RD management is still based on preliminary evidence, and there is great variability in the topical agents and dressings used in practice by radiation oncologists to prevent and treat RD. Regardless of the approach used, PD-1 Resistant Head and Neck Cancer management have two major objectives, prevention of PD-1 Resistant Head and Neck Cancer (Prophylaxis) and treatment of PD-1 Resistant Head and Neck Cancer.

PD-1 Resistant Head and Neck Cancer Epidemiology

The PD-1 Resistant Head and Neck Cancer symptoms-epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for the major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions undertaken.


Key Findings

The total incident cases of PD-1 Resistant Head and Neck Cancer are increasing during the study period, i.e., 2018–2030.


The disease epidemiology covered in the report provides historical as well as forecasted PD-1 Resistant Head and Neck Cancer symptoms epidemiology segmented as the Head and Neck cancer diagnosed patients, PD-1 treated patients and PD-1 refractory patients. The report includes PD-1 Resistant Head and Neck Cancer symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea, and Taiwan from 2018 to 2030.

Country-wise PD-1 Resistant Head and Neck Cancer Epidemiology

The epidemiology segment also provides the PD-1 Resistant Head and Neck Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea, and Taiwan.


The total incident cases of PD-1 refractory patients of PD-1 Resistant Head and Neck Cancer-associated in the mentioned countries was 11,940 in 2020.

PD-1 Resistant Head and Neck Cancer Drug Chapters

The PD-1 Resistant Head and Neck Cancer report’s drug chapter segment encloses the detailed analysis of PD-1 Resistant Head and Neck Cancer’s early-stage (Phase I, II, and III) pipeline drugs. It also helps understand the PD-1 Resistant Head and Neck Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


PD-1 Resistant Head and Neck Cancer Emerging Drug


Monalizumab (IPH2201): AstraZeneca/Innate Pharma

Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T-cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed on cancer cells of many solid tumors and hematological malignancies.


Buparlisib: Adlai Nortye Biopharma

Buparlisib is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors. Buparlisib significantly inhibited tumor growth in the animal model and showed a dose-response trend in anti-PD-1 refractory tumor-bearing mice. The dose range of buparlisib was consistent with previous preclinical studies conducted with BKM120 (Buparlisib, AN2025) by Novartis.

Products detail in the report…

PD-1 Resistant Head and Neck Cancer Market Outlook

The PD-1 Resistant Head and Neck Cancer market outlook helps build a detailed comprehension of the historical, current, and forecasted PD-1 Resistant Head and Neck Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of PD-1 Resistant Head and Neck Cancer market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the PD-1 Resistant Head and Neck Cancer market in the mentioned countries is expected to grow in the study period 2018–2030.


Although ICI is a successful new approach in cancer therapy, these checkpoint inhibitors may also lead to a loss of immune tolerance of healthy tissue, which results in various side effects, referred to as immune-related adverse events (irAEs). According to few references, up to one-fourth of patients on ipilimumab monotherapy and about the same percentage of patients on combined therapy suffer from severe (grade 3 or 4) enterocolitis. According to Burla (2020), overall, 15–25% of patients on single immunotherapy and about 65% of patients on combined immunotherapy suffer from grade 3 or grade 4 irAEs.


Immuno-oncology agents, including immune checkpoint inhibitors (ICIs), have revolutionized the treatment of a range of cancer types. Checkpoint molecules suppress T-cell function through various mechanisms and are exploited by tumor cells to evade the host immune attack. ICIs counteract this immunosuppression and restore immune responses against cancer.


Key Findings

This section includes a glimpse of the PD-1 Resistant Head and Neck Cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.


The market size of PD-1 Resistant Head and Neck Cancer in the major markets was USD 0.0 million in 2020.


The United States Market Outlook

This section provides the total PD-1 Resistant Head and Neck Cancer market size and market size by therapies in the United States.


The United States accounts for the largest market size of PD-1 Resistant Head and Neck Cancer compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), Japan, China, South Korea, and Taiwan.


EU-5 Countries: Market Outlook

The total PD-1 Resistant Head and Neck Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total PD-1 Resistant Head and Neck Cancer Market Size and Market Size by therapies in Japan are also mentioned.


China Market Outlook

The total PD-1 Resistant Head and Neck Cancer Market Size and Market Size by therapies in China are also mentioned.


South Korea Market Outlook

The total PD-1 Resistant Head and Neck Cancer Market Size and Market Size by therapies in South Korea are also mentioned.


Taiwan Market Outlook

The total PD-1 Resistant Head and Neck Cancer Market Size and Market Size by therapies in Taiwan are also mentioned.

PD-1 Resistant Head and Neck Cancer Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the PD-1 Resistant Head and Neck Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 


This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again help investigate factors important in the market uptake and in making financial and regulatory decisions.

PD-1 Resistant Head and Neck Cancer Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses PD-1 Resistant Head and Neck Cancer’s key players involved in developing targeted therapeutics.


Major players include AstraZeneca/Innate Pharma, Adlai Nortye Biopharma, Rakuten Medical, Kymab Limited, and Debiopharm International SA.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for PD-1 Resistant Head and Neck Cancer emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs’ and SMEs’ opinions working in the PD-1 Resistant Head and Neck Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or PD-1 Resistant Head and Neck Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the PD-1 Resistant Head and Neck Cancer Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of PD-1 Resistant Head and Neck Cancer, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the PD-1 Resistant Head and Neck Cancer epidemiology and treatment in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.
  • Additionally, an all-inclusive account of both the current and emerging therapies for PD-1 Resistant Head and Neck Cancer is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the PD-1 Resistant Head and Neck Cancer market, historical and forecasted, is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global PD-1 Resistant Head and Neck Cancer market.

Report Highlights

  • In the coming years, the PD-1 Resistant Head and Neck Cancer market is set to change due to the rising awareness of the disease and the favorable environment for new anti-infective modalities, expanding the market’s size to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence PD-1 Resistant Head and Neck Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for PD-1 Resistant Head and Neck Cancer. The launch of emerging therapies will significantly impact the PD-1 Resistant Head and Neck Cancer market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

PD-1 Resistant Head and Neck Cancer Report Insights

  • Patient Population
  • Therapeutic Approaches
  • PD-1 Resistant Head and Neck Cancer Pipeline Analysis
  • PD-1 Resistant Head and Neck Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

PD-1 Resistant Head and Neck Cancer Report Key Strengths

  • 10-years Forecast
  • The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan Coverage
  • PD-1 Resistant Head and Neck Cancer Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

PD-1 Resistant Head and Neck Cancer Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the PD-1 Resistant Head and Neck Cancer market share (%) distribution in 2018, and how would it look in 2030?
  • What would be the PD-1 Resistant Head and Neck Cancer total market Size as well as market Size by therapies across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan during the study period (2018–2030)?
  • What are the market’s key findings across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan, and which country will have the largest PD-1 Resistant Head and Neck Cancer market size during the study period (2018–2030)?
  • At what CAGR, the PD-1 Resistant Head and Neck Cancer market is expected to grow by the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan during the study period (2018–2030)?
  • What would be the PD-1 Resistant Head and Neck Cancer market outlook across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan during the study period (2018–2030)?
  • What would be the PD-1 Resistant Head and Neck Cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of PD-1 Resistant Head and Neck Cancer?
  • What is the historical PD-1 Resistant Head and Neck Cancer patient pool in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan?
  • What would be the forecasted patient pool of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan?
  • What will be the growth opportunities in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan concerning the patient population about PD-1 Resistant Head and Neck Cancer?
  • Out of all the countries, which country would have the largest incident PD-1 Resistant Head and Neck Cancer population during the study period (2018–2030)?
  • At what CAGR is the population expected to grow by the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan during the study period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of PD-1 Resistant Head and Neck Cancer along with the approved therapy?
  • What are the current treatment guidelines for the treatment of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan?
  • What are the PD-1 Resistant Head and Neck Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, and safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of PD-1 Resistant Head and Neck Cancer?
  • How many therapies are developed by each company for the treatment of PD-1 Resistant Head and Neck Cancer?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of PD-1 Resistant Head and Neck Cancer?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to PD-1 Resistant Head and Neck Cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for PD-1 Resistant Head and Neck Cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for PD-1 Resistant Head and Neck Cancer?
  • What are the global historical and forecasted markets of PD-1 Resistant Head and Neck Cancer?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the PD-1 Resistant Head and Neck Cancer market.
  • To understand the future market competition in the PD-1 Resistant Head and Neck Cancer market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the PD-1 Resistant Head and Neck Cancer market.
  • To understand the future market competition in the PD-1 Resistant Head and Neck Cancer market.

1. Key Insights

2. Report Introduction

3. PD-1 Resistant Head and Neck Cancer Market Overview at a Glance

3.1. Patient Share (%) Distribution of PD-1 Resistant Head and Neck Cancer in 2018

3.2. Market Share (%) Distribution of PD-1 Resistant Head and Neck Cancer in 2030

4. Executive Summary of PD-1 Resistant Head and Neck Cancer

5. Disease Background and Overview

5.1. Pathogenesis

5.2. Molecular Genetics of Head and Neck Cancer

5.3. Types of Head and Neck Cancer

5.4. Symptoms

5.5. Risk factors

5.6. Histopathology

5.7. Diagnosis

5.8. Staging

5.9. NCCN Guidelines

5.10. EHNSe-ESMOe-ESTRO Clinical Practice Guidelines for Squamous cell carcinoma

5.11. ESMO-EURACAN Clinical Practice Guidelines for Nasopharyngeal carcinoma

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. PD-1 refractory patients in 7MM, China, South Korea, and Taiwan

6.3. Epidemiology of Checkpoint Inhibitors refractory cancer

6.4. The United States

6.4.1. Head and Neck cancer diagnosed patients in the United States

6.4.2. PD-1 treated patients in the United States

6.4.3. PD-1 refractory patients in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Head and Neck cancer diagnosed patients in Germany

6.5.1.2. PD-1 treated patients in Germany

6.5.1.3. PD-1 refractory patients in Germany

6.5.2. France

6.5.2.1. Head and Neck cancer diagnosed patients in France

6.5.2.2. PD-1 treated patients in France

6.5.2.3. PD-1 refractory patients in France

6.5.3 Italy

6.5.3.1. Head and Neck cancer diagnosed patients in Italy

6.5.3.2. PD-1 treated patients in Italy

6.5.3.3. PD-1 refractory patients in Italy

6.5.4. Spain

6.5.4.1. Head and Neck cancer diagnosed patients in Spain

6.5.4.2. PD-1 treated patients in Spain

6.5.4.3. PD-1 refractory patients in Spain

6.5.5. United Kingdom

6.5.5.1. Head and Neck cancer diagnosed patients in the United Kingdom

6.5.5.2. PD-1 treated patients in the United Kingdom

6.5.5.3. PD-1 refractory patients in the United Kingdom

6.6. Japan

6.6.1. Head and Neck cancer diagnosed patients in Japan

6.6.2. PD-1 treated patients in Japan

6.6.3. PD-1 refractory patients in Japan

6.7. China

6.7.1. Head and Neck cancer diagnosed patients in China

6.7.2. PD-1 treated patients in China

6.7.3. PD-1 refractory patients in China

6.8. South Korea

6.8.1. Head and Neck cancer diagnosed patients in South Korea

6.8.2. PD-1 treated patients in South Korea

6.8.3. PD-1 refractory patients in South Korea

6.9. Taiwan

6.9.1. Head and Neck cancer diagnosed patients in Taiwan

6.9.2. PD-1 treated patients in Taiwan

6.9.3. PD-1 refractory patients in Taiwan

7. Organizations contributing towards PD-1 Resistant Head and Neck Cancer

8. Case Reports

9. Emerging Therapies

9.1. Key Cross Competition

9.2. NT219: TyrNovo Ltd./Purple Biotech Ltd.

9.2.1. Drug Description

9.2.2. Other development activities

9.2.3. Clinical Development

9.2.4. Safety and Efficacy

9.2.5. Product Profile

9.3. ASTX727 (Decitabine and cedazuridine): AstraZeneca/Astex Pharmaceuticals, Inc.

9.3.1. Drug Description

9.3.2. Clinical Development

9.3.3. Product Profile

9.4. Monalizumab: AstraZeneca/Innate Pharma

9.4.1. Drug Description

9.4.2. Other development activities

9.4.3. Clinical Development

9.4.4. Safety and Efficacy

9.4.5. Product Profile

9.5. Buparlisib: Adlai Nortye Biopharma

9.5.1. Drug Description

9.5.2. Other development activities

9.5.3. Clinical Development

9.5.4. Safety and Efficacy

9.5.5. Product Profile

9.6. Enfortumab Vedotin: Astellas Pharma/Seattle Genetics

9.6.1. Drug Description

9.6.2. Other development activities

9.6.3. Clinical Development

9.6.4. Product Profile

9.7. Cetuximab sarotalocan: Rakuten Medical

9.7.1. Drug Description

9.7.2. Other development activities

9.7.3. Clinical development

9.7.4. Safety and Efficacy

9.7.5. Product Profile

9.8. Afatinib: Boehringer Ingelheim

9.8.1. Drug Description

9.8.2. Other development activities

9.8.3. Clinical development

9.8.4. Product Profile

9.9. Nemvaleukin alfa/ALKS 4230: Alkermes

9.9.1. Drug Description

9.9.2. Other development activities

9.9.3. Clinical development

9.9.4. Product Profile

9.10. Anktiva/N-803: Alkermes

9.10.1. Drug Description

9.10.2. Clinical development

9.10.3. Product Profile

9.11. Tisotumab vedotin: Seagen Inc./Genmab

9.11.1. Drug Description

9.11.2. Other development activities

9.11.3. Clinical Development

9.11.4. Product Profile

9.12. Eftilagimod alpha: Immutep S.A./Merck Sharp & Dohme Corp.

9.12.1. Drug Description

9.12.2. Other development activities

9.12.3. Clinical Development

9.12.4. Safety and Efficacy

9.12.5. Product Profile

9.13. Voyager V-1 (VSV-IFNβ-NIS): Vyriad, Inc.

9.13.1. Drug Description

9.13.2. Other development activities

9.13.3. Clinical Development

9.13.4. Product Profile

9.14. Sacituzumab govitecan: Immunomedics, Inc.

9.14.1. Drug Description

9.14.2. Other development activities

9.14.3. Clinical Development

9.14.4. Product Profile

9.15. Ladiratuzumab vedotin: Seagen Inc.

9.15.1. Drug Description

9.15.2. Clinical Development

9.15.3. Product Profile

9.16. Durvalumab + Other Therapy: AstraZeneca

9.16.1. Product Description

9.16.2. Clinical Development

9.16.3. Product Profile

9.17. KY1044: Kymab Limited

9.17.1. Product Description

9.17.2. Other Developmental Activities

9.17.3. Clinical Development

9.17.4. Safety and Efficacy

9.17.5. Product Profile

9.18. Copanlisib: Bayer

9.18.1. Drug Description

9.18.2. Clinical Development

9.18.3. Product Profile

9.19. Feladilimab: GlaxoSmithKline/MedImmune LLC

9.19.1. Drug Description

9.19.2. Clinical Development

9.19.3. Product Profile

9.20. BMS-986315: Bristol-Myers Squibb

9.20.1. Drug Description

9.20.2. Clinical Development

9.20.3. Product Profile

9.21. Etigilimab: Mereo BioPharma

9.21.1. Drug Description

9.21.2. Clinical Development

9.21.3. Product Profile

9.22. Xevinapant (Debio 1143): Debiopharm International SA

9.22.1. Drug Description

9.22.2. Other Developmental Activities

9.22.3. Clinical Development

9.22.4. Safety and Efficacy

9.22.5. Product Profile

9.23. NKTR-255: Nektar Therapeutics

9.23.1. Drug Description

9.23.2. Regulatory Milestones

9.23.3. Clinical Development

9.23.4. Product Profile

9.24. ABI-009: Aadi Bioscience

9.24.1. Drug Description

9.24.2. Regulatory Milestones

9.24.3. Clinical Development

9.24.4. Product Profile

9.25. Relatlimab: Bristol-Myers Squibb

9.25.1. Drug Description

9.25.2. Clinical Development

9.25.3. Product Profile

9.26. Lenvatinib: Merck Sharp & Dohme Corp. and Eisai

9.26.1. Drug Description

9.26.2. Regulatory Milestones

9.26.3. Clinical Development

9.26.4. Product Profile

9.27. Aldesleukin: Clinigen

9.27.1. Drug Description

9.27.2. Regulatory Milestones

9.27.3. Clinical Development

9.27.4. Product Profile

9.28. Avelumab: Pfizer

9.28.1. Drug Description

9.28.2. Clinical Development

9.28.3. Product Profile

9.29. exoSTING: Codiak BioSciences

9.29.1. Drug Description

9.29.2. Clinical Development

9.29.3. Product Profile

9.30. OC-001: Ocellaris Pharma

9.30.1. Drug Description

9.30.2. Clinical Development

9.30.3. Product Profile

9.31. Atezolizumab: Genentech

9.31.1. Drug Description

9.31.2. Regulatory Milestones

9.31.3. Clinical Development

9.31.4. Safety and efficacy

9.31.5. Product Profile

10. PD-1 Resistant Head and Neck Cancer: 7 Major Market Analysis

10.1. Key Findings

10.2. Market Size of PD-1 Resistant Head and Neck Cancer in 7MM, China, South Korea, and Taiwan

10.3. Market Outlook

10.4. United States Market Size

10.4.1. Total Market Size of PD-1 Resistant Head and Neck Cancer in the United States

10.4.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in the United States

10.5. EU-5 Market Size

10.5.1. Germany

10.5.1.1. Total Market Size of PD-1 Resistant Head and Neck Cancer in Germany

10.5.1.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in Germany

10.5.2. France

10.5.2.1. Total Market Size of PD-1 Resistant Head and Neck Cancer in France

10.5.2.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in France

10.5.3. Italy

10.5.3.1. Total Market Size of PD-1 Resistant Head and Neck Cancer in Italy

10.5.3.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in Italy

10.5.4. Spain

10.5.4.1. Total Market Size of PD-1 Resistant Head and Neck Cancer in Spain

10.5.4.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in Spain

10.5.5. United Kingdom

10.5.5.1. Total Market Size of PD-1 Resistant Head and Neck Cancer in the United Kingdom

10.5.5.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in the United Kingdom

10.6. Japan

10.6.1. Total Market size of PD-1 Resistant Head and Neck Cancer in Japan

10.6.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in Japan

10.7. China

10.7.1. Total Market size of PD-1 Resistant Head and Neck Cancer in China

10.7.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in China

10.8. South Korea

10.8.1. Total Market size of PD-1 Resistant Head and Neck Cancer in South Korea

10.8.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in South Korea

10.9. Taiwan

10.9.1. Total Market size of PD-1 Resistant Head and Neck Cancer in Taiwan

10.9.2. Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in Taiwan

11. KOL Views

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Unmet Needs

16. Appendix

16.1. Bibliography

16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Table

Table 1: Summary of PD-1/ PD-L1 Resistant Head and Neck Cancer, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Tumor-node Metastasis Classification of Human Papillomavirus (HPV)–Positive and HPV-Negative Oropharyngeal Cancer

Table 3: Prognostic Stages According to the TNM Classification*

Table 4: Work-up for staging and diagnosis

Table 5: Management of oral cavity cancer (stage I–IVB) excluding lip carcinoma

Table 6: Management of laryngeal cancer (stage I–IVB)

Table 7: Management of oropharyngeal cancer (p16-negative stage I–IVB; p16-positive stage I–III)

Table 8: Management of hypopharyngeal cancer (stage I–IVB)

Table 9: Management of recurrent and/or metastatic disease not amenable to curative RT or surgery

Table 10: Diagnostic work-up

Table 11: Total PD-1 refractory population in 7MM, China, South Korea, and Taiwan (2018–2030)

Table 12: Incidence of Head and Neck cancer in the United States (2018–2030)

Table 13: PD-1 treated patients in the United States (2018–2030)

Table 14: PD-1 refractory patients in the United States (2018–2030)

Table 15: Incidence of Head and Neck Cancer in Germany (2018–2030)

Table 16: PD-1 treated patients in Germany (2018–2030)

Table 17: PD-1 refractory patients in Germany (2018–2030)

Table 18: Incidence of Head and Neck Cancer in France (2018–2030)

Table 19: PD-1 treated patients in France (2018–2030)

Table 20: PD-1 refractory patients in France (2018–2030)

Table 21: Incidence of Head and Neck Cancer in Italy (2018–2030)

Table 22: PD-1 treated patients in Italy (2018–2030)

Table 23: PD-1 refractory patients in Italy (2018–2030)

Table 24: Incidence of Head and Neck Cancer in Spain (2018–2030)

Table 25: PD-1 treated patients in Spain (2018–2030)

Table 26: PD-1 refractory patients in Spain (2018–2030)

Table 27: Incidence of Head and Neck cancer in the United Kingdom (2018–2030)

Table 28: PD-1 treated patients in the United Kingdom (2018–2030)

Table 29: PD-1 refractory patients in the United Kingdom (2018–2030)

Table 30: Incidence of Head and Neck Cancer in Japan (2018–2030)

Table 31: PD-1 treated patients in Japan (2018–2030)

Table 32: PD-1 refractory patients in Japan (2018–2030)

Table 33: Incidence of Head and Neck cancer in China (2018–2030)

Table 34: PD-1 treated patients in China (2018–2030)

Table 35: PD-1 refractory patients in China (2018–2030)

Table 36: Incidence of Head and Neck cancer in South Korea (2018–2030)

Table 37: PD-1 treated patients in South Korea (2018–2030)

Table 38: PD-1 refractory patients in South Korea (2018–2030)

Table 39: Incidence of Head and Neck cancer in Taiwan (2018–2030)

Table 40: PD-1 treated patients in Taiwan (2018–2030)

Table 41: PD-1 treated patients in Taiwan (2018–2030)

Table 42: Organizations contributing toward the fight against head and neck cancer

Table 43: NT219, Clinical Trial Description, 2021

Table 44: ASTX727, Clinical Trial Description, 2021

Table 45: Monalizumab, Clinical Trial Description, 2021

Table 46: Buparlisib, Clinical Trial Description, 2021

Table 47: Enfortumab Vedotin, Clinical Trial Description, 2021

Table 48: ASP-1929, Clinical Trial Description, 2021

Table 49: Afatinib, Clinical Trial Description, 2021

Table 50: ALKS 4230, Clinical Trial Description, 2021

Table 51: N- 803, Clinical Trial Description, 2021

Table 52: Tisotumab vedotin, Clinical Trial Description, 2021

Table 53: Eftilagimod alpha, Clinical Trial Description, 2021

Table 54: Voyager-V1, Clinical Trial Description, 2021

Table 55: Sacituzumab govitecan, Clinical Trial Description, 2021

Table 56: Ladiratuzumab vedotin, Clinical Trial Description, 2021

Table 57: Durvalumab + Other Therapy, Clinical Trial Description, 2021

Table 58: KY1044, Clinical Trial Description, 2021

Table 59: Copanlisib, Clinical Trial Description, 2021

Table 60: Feladilimab, Clinical Trial Description, 2021

Table 61: BMS-986315, Clinical Trial Description, 2021

Table 62: Etigilimab, Clinical Trial Description, 2021

Table 63: Xevinapant, Clinical Trial Description, 2021

Table 64: NKTR-255, Clinical Trial Description, 2021

Table 65: ABI-009, Clinical Trial Description, 2021

Table 66: Relatlimab and Ipilimumab, Clinical Trial Description, 2021

Table 67: Lenvatinib, Clinical Trial Description, 2021

Table 68: Aldesleukin, Clinical Trial Description, 2021

Table 69: Avelumab, Clinical Trial Description, 2021

Table 70: exoSTING, Clinical Trial Description, 2021

Table 71: OC-001, Clinical Trial Description, 2021

Table 72: Atezolizumab, Clinical Trial Description, 2021

Table 73: 7 Major Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 74: United States Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 75: United States Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Table 76: Germany Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 77: Germany Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Table 78: France Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 79: France Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Table 80: Italy Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 81: Italy Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Table 82: Spain Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 83: Spain Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Table 84: United Kingdom Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 85: United Kingdom Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Table 86: Japan Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 87: Japan Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Table 88: China Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 89: China Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Table 90: South Korea Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 91: South Korea Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Table 92: Taiwan Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Table 93: Taiwan Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Histologic features of head and neck squamous cell carcinoma (HNSCC)

Figure 2: Updates in version 1.2021 of the NCCN guidelines for Head and Neck Cancers from version 2.2020 include:

Figure 3: Updates in version 1.2021 of the NCCN guidelines for Head and Neck Cancers from version 2.2020 include:

Figure 4: Treatment algorithm for stage I-IVA NPC

Figure 5: Treatment algorithm for recurrent and/or metastatic NPC

Figure 6: Total PD-1 refractory population in 7MM, China, South Korea, and Taiwan (2018–2030)

Figure 7: Incidence of Head and Neck cancer in the United States (2018–2030)

Figure 8: PD-1 treated patients in the United States (2018–2030)

Figure 9: PD-1 refractory patients in the United States (2018–2030)

Figure 10: Incidence of Head and Neck Cancer in Germany (2018–2030)

Figure 11: PD-1 treated patients in Germany (2018–2030)

Figure 12: PD-1 refractory patients in Germany (2018–2030)

Figure 13: Incidence of Head and Neck Cancer in France (2018–2030)

Figure 14: PD-1 treated patients in France (2018–2030)

Figure 15: PD-1 refractory patients in France (2018–2030)

Figure 16: Incidence of Head and Neck Cancer in Italy (2018–2030)

Figure 17: PD-1 treated patients in Italy (2018–2030)

Figure 18: PD-1 refractory patients in Italy (2018–2030)

Figure 19: Incidence of Head and Neck Cancer in Spain (2018–2030)

Figure 20: PD-1 treated patients in Spain (2018–2030)

Figure 21: PD-1 refractory patients in Spain (2018–2030)

Figure 22: Incidence of Head and Neck cancer in the United Kingdom (2018–2030)

Figure 23: PD-1 treated patients in the United Kingdom (2018–2030)

Figure 24: PD-1 refractory patients in the United Kingdom (2018–2030)

Figure 25: Incidence of Head and Neck Cancer in Japan (2018–2030)

Figure 26: PD-1 treated patients in Japan (2018–2030)

Figure 27: PD-1 refractory patients in Japan (2018–2030)

Figure 28: Incidence of Head and Neck cancer in China (2018–2030)

Figure 29: PD-1 treated patients in China (2018–2030)

Figure 30: PD-1 refractory patients in China (2018–2030)

Figure 31: Incidence of Head and Neck cancer in South Korea (2018–2030)

Figure 32: PD-1 treated patients in South Korea (2018–2030)

Figure 33: PD-1 refractory patients in South Korea (2018–2030)

Figure 34: Incidence of Head and Neck cancer in Taiwan (2018–2030)

Figure 35: PD-1 treated patients in Taiwan (2018–2030)

Figure 36: PD-1 refractory patients in Taiwan (2018–2030)

Figure 37: 7 Major Market Size of PD-1 Resistant Head and Neck Cancer in USD Million (2018–2030)

Figure 38: Market Size of PD-1 Resistant Head and Neck Cancer in the United States, USD Million (2018–2030)

Figure 39: The United States Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million

Figure 40: Market Size of PD-1 Resistant Head and Neck Cancer in Germany, USD Million (2018–2030)

Figure 41: Germany Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million

Figure 42: Market Size of PD-1 Resistant Head and Neck Cancer in France, USD Million (2018–2030)

Figure 43: France Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million

Figure 44: Market Size of PD-1 Resistant Head and Neck Cancer in Italy, USD Million (2018–2030)

Figure 45: Italy Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million

Figure 46: Market Size of PD-1 Resistant Head and Neck Cancer in Spain, USD Million (2018–2030)

Figure 47: Spain Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million

Figure 48: Market Size of PD-1 Resistant Head and Neck Cancer in the United Kingdom, USD Million (2018–2030)

Figure 49: The United Kingdom Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million

Figure 50: Market Size of PD-1 Resistant Head and Neck Cancer in Japan, USD Million (2018–2030)

Figure 51: Japan Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million

Figure 52: Market Size of PD-1 Resistant Head and Neck Cancer in China, USD Million (2018–2030)

Figure 53: China Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million

Figure 54: Market Size of PD-1 Resistant Head and Neck Cancer in South Korea, USD Million (2018–2030)

Figure 55: South Korea Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million (2018–2030)

Figure 56: Market Size of PD-1 Resistant Head and Neck Cancer in Taiwan, USD Million (2018–2030)

Figure 57: Taiwan Market Size of PD-1 Resistant Head and Neck Cancer by Therapies in USD Million

• TyrNovo Ltd./Purple Biotech Ltd.

• AstraZeneca/Astex Pharmaceuticals, Inc.

• AstraZeneca/Innate Pharma

• Adlai Nortye Biopharma

• Astellas Pharma/Seattle Genetics

• Rakuten Medical

• Boehringer Ingelheim

• Alkermes

• Alkermes

• Seagen Inc./Genmab

• Immutep S.A./Merck Sharp & Dohme Corp.

• Vyriad, Inc.

• Immunomedics, Inc.

• Seagen Inc.

• AstraZeneca

• Kymab Limited

• Bayer

• GlaxoSmithKline/MedImmune LLC

• Mereo BioPharma

• Debiopharm International SA

• Nektar Therapeutics

• Aadi Bioscience

• Bristol-Myers Squibb

• Merck Sharp & Dohme Corp. and Eisai

• Clinigen

• Pfizer

• Codiak BioSciences

• Ocellaris Pharma

• Genentech

  • Tags:
  • PD-1 Resistant Head and Neck Cancer...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...
  • PD-1 Resistant Head and Neck Cance...

Forward to Friend

Need A Quote